Treatment of hepatitis C virus in HIV patients: A review

AIDS

Volumn 19, Issue SUPPL. 3, 2005, Pages

  Kontorinis, Nickolas ^a   Agarwal, Kaushik ^a   Dieterich, Douglas T ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

Co infection; Hepatitis C virus; HIV; Pegylated interferon; Ribavirin

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE;

CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE TRANSMISSION; EVIDENCE BASED MEDICINE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MEDICAL LITERATURE; MORTALITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL;

EID: 27944439273     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000192086.64432.e7     Document Type: Review

References (51)

1. Manns MP, McHutchison JC, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
3. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350:2265-2271.
4. Perez-Olmeda M, Soriano V, Asensi V, Morales D, Romero M, Ochoa A, et al. Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. AIDS Res Hum Retroviruses 2003; 19:1083-1089.
5. Soriano V, Garcia-Samaniego J, Gutierrez M, Bravo R, Gonzalez-Lahoz J. High morbidity and mortality of chronic viral liver disease in HIV-infected individuals in Spain. J Infect 1994; 28:100-102.
6. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058.
7. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-287.
8. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M. Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis 2001; 33:1793-1795.
9. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24:211-217.
10. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34:730-739.
11. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003; 23:173-182.
12. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev 2003; 5:36-43.
13. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
14. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001; 8:87-95.
15. Barrera JM. Diagnostic tests for hepatitis C virus infection. Nephrol Dial Transplant 2000; 15 (Suppl. 8):15-18.
16. Barrera JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, et al. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995; 68:15-18.
17. Ferreira-Gonzalez A, Shiffman ML. Use of diagnostic testing for managing hepatitis C virus infection. Semin Liver Dis 2004; 24 (Suppl. 2):9-18.
18. George SL, Gebhardt J, Klinzman D, Foster MB, Patrick KD, Schmidt WN, et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr 2002; 31:154-162.
19. Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000; 38:575-577.
20. Sherman KE. Implications of peginterferon use in special populations infected with HCV. Semin Liver Dis 2003; 23 (Suppl. 1):47-52.
21. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
22. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837.
23. Sherman KE, Rouster SD, Horn PS. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin Infect Dis 2002; 35:482-487.
24. Bonacini M, Govindarajan S, Blatt LM, Schmid P, Conrad A, Lindsay KL. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999; 6:203-208.
25. Sherman KE, Rouster SD, Mendenhall C, Thee D. Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. Hepatology 1999; 30:265-270.
26. Hino K, Yamaguchi Y, Fujiwara D, Katoh Y, Korenaga M, Okazaki M, et al. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study. J Viral Hepat 2000; 7:36-42.
27. Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23:585-591.
28. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, et al. The impact of steatosis on disease progression and earlyÂand sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40:484-490.
29. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:1221-1231.
30. Baker R, Kotler D, Carr A, Torres RA. Altered body shape in HIV disease: a side effect of therapy? AIDS Patient Care STDS 1999; 13:395-402.
31. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000; 30 (Suppl. 2):S135-S142.
32. Agarwal K, Uriel A, Moorehead L, Fiel M, Kontorinis N, Sulkowski M, Dieterich D. Baseline insulin resistance demonstrates negative predictive value for week 12 early virological response to antiviral therapy in hepatitis C and HIV co-infected patients. In: 59th Annual AASLD Meeting. Boston, MA, October 2004 [Abstract 424].
33. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30:787-793.
34. Ohnishi K, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91:1374-1379.
35. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
36. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459.
37. Braun M, Vierling JM. The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver Transplant 2003; 9 (Suppl. 11):S79-S89.
38. Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med 2000; 160:3365-3373.
39. Coll S, Sola R, Vila MC, Seoane A. Treatment of hepatitis C HIV co-infected patients with interferon: controlled study. In: Program and abstracts of the 50th Annual Meeting of the American Association for the Study of Liver Diseases (Dallas). Philadelphia: WB Sanders; 1999. p. 199A [abstract 153].
40. Sulkowski M, Felizarta F, Smith C, Slim J, Berggren R, Goodman R, et al. Daily versus thrice-weekly interferon Alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr 2004; 35:464-472.
41. Brau N, Rodriguez-Torres M, Prokupek D, Bonacini M, Giffen CA, Smith JJ, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology 2004; 39:989-998.
42. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003; 23 (Suppl. 1):23-28.
43. Perez-Olmeda M, Nunez M, Romero M, Gonzalez J, Castro A, Arribas JR, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-1028.
44. Perronne C, Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel F, et al. Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon-alfa-2b plus ribavirin vs interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract # 117LB].
45. Uriel A, Carriero D, Lucas J, Reichenberg A, Freemantle H, Goldman D, et al. Efficacy of interferon and ribavirin therapy in HIV/HCV co-infected patients: sustained virological response is associated with a rise in CD 4 lymphocyte count. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract # 825].
46. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (Suppl. 1):237-244.
47. Dieterich DT. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis 2002; 185 (Suppl. 2):S128-S137.
48. Kakuda TN, Brinkman K. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357:1802-1803.
49. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16:813-828.
50. Hennessy M, Mulcahy F, Spiers P, Hopkins S, Hoggard P, Kewn S, et al. Differential effects of combined pegylated interferon and ribavirin therapy on intracellular nucleotide triphosphate levels in HIV/HCV co-infected patients: a potential mechanism for enhanced toxicity. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract # 822].
51. Soriano V, Camino N, Perez-Olmeda M, et al. Hepatitis C virus RNA clearance in HIV-co-infected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract # 819].